JP6582029B2 - Ophthalmic composition liquid and method of use thereof - Google Patents

Description

  The present invention relates to an ophthalmic composition liquid and a method for using the same.

  Conventionally, as an ophthalmic composition liquid, for example, a composition containing a cooling agent, a polyoxyethylene-polyoxypropylene block copolymer, hydroxypropylmethylcellulose, and a polyhydric alcohol in a predetermined ratio has been proposed. (For example, refer to Patent Document 1). In this composition liquid, the moisturizing effect can be satisfactorily exhibited, the wettability of the contact lens can be ensured to a high degree, and a further excellent usability can be realized, and the storage stability can also be improved. Moreover, as an ophthalmic composition liquid, what is used for the soft contact lens containing a menthol and contains polyoxyethylene sorbitan ester is proposed (for example, refer patent document 2). In this composition liquid, when it comes into contact with a soft contact lens, the wettability is improved, and by suppressing the decrease in the moisture content, it is possible to further reduce the occurrence of dry feeling and foreign object feeling that can occur when the soft contact lens is worn. Yes. Moreover, as an ophthalmic composition liquid, what contains vitamin A and polyoxyethylene polyoxypropylene glycol, and the content of a cationic surfactant and a hydrophobic preservative is below a predetermined amount is proposed ( For example, see Patent Document 3). In this composition liquid, it is said that the therapeutic effect of vitamin A on corneal / conjunctival damage is improved.

Japanese Patent Laying-Open No. 2005-8568 JP-A-11-130667 JP 2011-6348 A

  By the way, a wide variety of contact lenses are currently distributed, and not only the monomer components that make up contact lenses, but also pigments (dyes), distribution storage liquid (packaging liquid) components, cutting or mold manufacturing methods, etc. There are various things ranging from manufacturing methods and modalities (days of use, hours of use). For this reason, it is difficult to discuss the suitability as a contact lens agent in the broad categories of conventional “soft (hydrous / non-hydrous, including silicone hydrogel)” and “hard (including oxygen-permeable hard)”. It has become. Therefore, it is necessary to comprehensively understand contact lenses, and a contact lens agent suitable for them is required. In Patent Documents 1 to 3 described above, although there are various effects, the difference in the material of the contact lens and the difference in the manufacturing method have not been studied in detail, and it has not been sufficient. As described above, it has been demanded to further improve the feeling of use of the contact lens, to further improve the safety of the contact lens and these ophthalmic preparations, and to eliminate the discomfort at the time of wearing the contact lens.

  This invention is made in view of such a subject, and provides the ophthalmic composition liquid which improved the usability | use_condition of a contact lens, and the safety | security as a contact lens or an ophthalmic agent, and its usage method. Main purpose.

As a result of diligent research to achieve the above-described object, the present inventors have found that the ratio of the average degree of polymerization is polyoxyethylene-polyoxypropylene glycol having a predetermined range, a polyvalent carboxylic acid and / or salt thereof, And an agent, and it is found that when the concentration of dibutylhydroxytoluene falls within a predetermined range, the usability of the contact lens and the safety as a contact lens or ophthalmic solution can be further improved. It came to be completed.

That is, the ophthalmic composition liquid of the present invention is
A ratio EO / PO of the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is 1.0 or more and 5.0 or less, and polyoxyethylene-polyoxypropylene glycol,
One or more selected from polyvalent carboxylic acids and polyvalent carboxylates;
A cooling agent,
The IC50 value is 1.0% or more, and the concentration of dibutylhydroxytoluene (BHT) in the composition liquid is less than 1.5 ppm.

The method of using the ophthalmic composition liquid of the present invention is as follows.
The ratio of the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is a polyoxyethylene-polyoxypropylene glycol having a ratio EO / PO in the range of 1.0 to 5.0, and a polyvalent carboxylic acid. 1 or more chosen from an acid and polyvalent carboxylate salt, and a cooling agent are contained, IC50 value is 1.0% or more, and the density | concentration of the dibutylhydroxytoluene (BHT) in a composition liquid is 1. The ophthalmic composition liquid having a concentration of less than 5 ppm is used for hard contact lenses and / or soft contact lenses manufactured by a mold manufacturing method.

  In the ophthalmic composition liquid and the method of using the ophthalmic composition of the present invention, it is possible to further improve the feeling of use of the contact lens and the safety as a contact lens wearing or ophthalmic agent. The present inventor, against the background of complicated contact lenses as described above, a variety of points to be solved, especially hard contact lenses manufactured by a mold manufacturing method, and composition for contact lenses suitable for them We conducted intensive research on the liquid. As a result, it was found that the combined use of poloxamers and cooling agents generally used in ophthalmic composition liquids is a factor that changes the base curve of hard contact lenses manufactured by a mold manufacturing method. The change in the base curve of the hard contact lens causes the contact lens wearing feeling to deteriorate and causes discomfort during wearing. Furthermore, as a result of earnest research on the wearing feeling of soft contact lenses, the combined use of poloxamers and cooling agents has an effect on the contact lens base curve during wearing as well as for soft contact lenses. The knowledge that it is a factor was acquired. The ratio EO / PO of the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is within a suitable range, and at least one selected from polyvalent carboxylic acids and polyvalent carboxylates is ophthalmic. It has been found that the change in the base curve of these contact lenses can be further reduced by adding to the composition liquid. Moreover, it discovered that the amount of lipid adhesion to a contact lens could be suppressed more by setting it as the said composition, for example. Furthermore, the present inventors have also found that the ophthalmic composition liquid can improve the refractive index of the contact lens, thereby obtaining visibility clarity at the time of wearing. These found advantages can improve the feeling of use of the contact lens, that is, the effect of reducing discomfort when wearing the hard contact lens or the soft contact lens. Moreover, the safety | security as a contact lens wearing or an ophthalmic agent can be improved more by setting it as the said composition including that BHT density | concentration is less than 1.5 ppm.

The ophthalmic composition liquid of the present invention is a polyoxyethylene polymer in which the ratio EO / PO between the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is 1.0 or more and 5.0 or less. It contains polyoxypropylene glycol (poloxamers; component A), one or more (component B) selected from polyvalent carboxylic acids and polyvalent carboxylates, and a cooling agent (component C). Further, the ophthalmic composition liquid of the present invention has an IC50 value of 1.0% or more, and the concentration of dibutylhydroxytoluene (BHT) in the ophthalmic composition liquid (formulation) is less than 1.5 ppm.

  The poloxamers as component A have various different forms such as a difference in average polymerization degree between propylene oxide and ethylene oxide, a block copolymer, a random copolymer, and an ethylenediamine derivative. A poloxamer is a block copolymer of propylene oxide and ethylene oxide in a narrow sense as described in United States Pharmacopeia NF32. However, in the present application, the poloxamer is a combination of various copolymers. Describe as a class. Among them, for example, poloxamer 124 (Pluronic (registered trademark) L-44, average molecular weight 2200), poloxamer 188 (Pluronic (registered trademark) F-68, average molecular weight 8400), poloxamer 235 (Pluronic (registered trademark) P-85, Average molecular weight 4600) and poloxamer 407 (Pluronic® F-127, Pronon® # 407P, average molecular weight 12600). Unilube (registered trademark) 70DP-950B, Unilube (registered trademark) 75DE-2620R, and the like. Further, as ethylenediamine derivatives, for example, Tetronic (registered trademark) 707 (average molecular weight 12000), Tetronic (registered trademark) 908 (average molecular weight 22500), Tetronic (registered trademark) 1107 (average molecular weight 14500), Tetronic 1307 (Average molecular weight 18600), Tetronic (registered trademark) 1508 (average molecular weight 26600) and the like. Among them, poloxamer 188, poloxamer 235, and poloxamer 407 (Pluronic (registered trademark) F-127) are preferable. , Pronon (registered trademark) # 407P), Unilube (registered trademark) 70DP-950B, Unilube (registered trademark) 75DE-2620R, Tetronic (registered trademark) 1107 are particularly preferable. The preferred ratio EO / PO of these poloxamers is in the range of 1.0 to 5.0, but more preferably in the range of 2.0 to 4.0. Poloxamers are commercially available from BASF Wyandotte Corporation, NOF Corporation, ADEKA Corporation and the like. At least one selected from these preferred poloxamers is selected and blended.

These poloxamers may produce propionaldehyde which is an impurity during production or storage. In order to prevent the generation of impurities, poloxamers may be pre-blended with, for example, dl-α tocopherol or dibutylhydroxytoluene (BHT) as an antioxidant. However, these antioxidants, especially composition liquids using BHT-containing raw materials, increase the cytotoxicity due to the blending of the antioxidants. Therefore, poloxamers that do not contain antioxidants such as BHT or are contained in low concentrations. It is further preferred to use Furthermore, there has been a problem that BHT is easily adsorbed and occluded in contact lens materials, and an effective solution has been achieved by incorporating a component that suppresses adsorption into the preparation. However, a more useful method has been desired. . That is, the BHT concentration in the ophthalmic composition liquid is less than 10 ppm, preferably less than 1.5 ppm, more preferably 1 ppm or less, and still more preferably 0.7 ppm or less. In making it into such a range, the compounding quantity of the raw material containing BHT is restrict | limited, A raw material is heated or humidified by a well-known method, and BHT is transpired and removed. Moreover, the raw material without an antioxidant is also commercially available. In this case, for example, Pronon (registered trademark) # 407P (polyoxyethylene (196) polyoxypropylene (67) glycol) manufactured by NOF Corporation, Unilube (registered trademark) 70DP-950B (polyoxyethylene (200) polyoxy) Propylene (70) glycol) is preferably used. In addition, when using the raw material poloxamers containing BHT for the ophthalmic composition liquid of this invention, the BHT density | concentration in ophthalmic composition liquid should be restrict | limited to the range of 0.001 ppm-0.7 ppm.

  The concentration of the component A in the ophthalmic composition liquid may be in a range that exhibits the effect of the present invention. Specifically, the concentration is preferably in the range of 0.0005% by mass to 5% by mass. A range of 0.001% by mass to 1.5% by mass is more preferable. When this concentration is 0.0005% by mass or more, a tear wet effect on the surface of the contact lens, a stain adhesion preventing effect, and an eyelid friction reducing effect are sufficiently obtained, and it is easy to apply as a contact lens solution. In addition, when the concentration is within 5% by mass, it is preferable from the viewpoint of contact lens specifications.

  Examples of the polyvalent carboxylic acid as component B include one or more selected from edetic acid, citric acid, hyaluronic acid, and carboxyvinyl polymer. Examples of the polyvalent carboxylate include one or more selected from edetate, citrate, hyaluronate, and carboxyvinyl polymer salt. The edetate includes disodium calcium edetate, sodium edetate, disodium edetate, disodium edetate, trisodium edetate, trisodium edetate, sodium edetate, edetate Examples include tetrasodium acid and tetrasodium edetate tetrahydrate. The edetic acid (salt) used by this invention may be used individually by 1 type, and may be used in combination of 2 or more type. The amount of edetic acid (salt) in the preparation is preferably in the range of 0.0001% by mass to 0.5% by mass, and more preferably in the range of 0.001% by mass to 0.1% by mass. Examples of the citrate include calcium citrate, sodium citrate hydrate, sodium dihydrogen citrate, and disodium citrate. Citric acid (salt) used in the present invention may be used alone or in combination of two or more. The blending amount of citric acid (salt) in the preparation is preferably in the range of 0.0001% by mass to 2% by mass, and more preferably in the range of 0.001% by mass to 1% by mass.

  Hyaluronic acid is a polymer composed of a basic structure (repeating unit) of GlcUA-GlcNAc in which glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc) are bound. Hyaluronic acid and a salt thereof used in the present invention are known compounds, and may be produced by a known method, or may be obtained as a commercial product. Hyaluronic acid and its salt may be used individually by 1 type, and may be used in combination of 2 or more type. The hyaluronic acid used in the present invention may be any of natural products, derived from chicken crown extraction, and synthetic products by fermentation. The molecular weight of hyaluronic acid used in the present invention is not particularly limited, but is a mass average molecular weight of 1 to 5 million, preferably 1,000 to 4 million, more preferably 10,000 to 3 million, and still more preferably 100,000 to 250. 10,000, particularly preferably 500,000 to 2,000,000. The salt of hyaluronic acid used in the present invention is not particularly limited as long as it is in the form of a pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable salt. Specifically, alkali metal salts such as sodium salt and potassium salt can be exemplified, and sodium hyaluronate is preferable. Sodium hyaluronate that conforms to or conforms to the standards of the 16th revised Japanese Pharmacopoeia, United States Pharmacopia, European Pharmacopoeia, etc. is more preferred. The hyaluronic acid salt used in the present invention may be used singly or in combination of two or more. The blending amount of hyaluronic acid (salt) in the preparation is preferably in the range of 0.0001 mass% to 1 mass%, more preferably in the range of 0.001 mass% to 0.5 mass%.

As carboxyvinyl polymer (CVP), alkali metal salts such as sodium salt and potassium salt of poly (meth) acrylic acid; monoethanolamine salt, diethanolamine salt and triethanolamine salt of poly (meth) acrylic acid An amine salt; an ammonium salt of poly (meth) acrylic acid or the like can be used. Of these, alkali metal salts are preferred. The poly (meth) acrylic acid or a salt thereof may be either a crosslinked type or a non-crosslinked type, and the molecular weight (viscosity standard) and the effective pH range are appropriately selected depending on the intended preparation. This CVP can use a commercial item. Commercially available products include Carbopol (trade name) (Lubrisol), Shintalen (trade name), Hibiswako (trade name) (Wako Pure Chemical Industries), Akpek (trade name) (Sumitomo Seika), Junron (product) Name) (Nippon Pure Chemicals) etc. can be used. CVP can be used alone or in combination of two or more. The blending amount of the carboxyvinyl polymer in the preparation is preferably in the range of 0.0001% by mass to 1% by mass, more preferably in the range of 0.001% by mass to 0.5% by mass.

  The concentration of Component B shown above in the ophthalmic composition liquid is within a range in which the effects of the present invention are exhibited, and may be in a range in which the filterability during production of the ophthalmic composition liquid is good. If the density range is shown above, the effect of suppressing the change in the base curve of the contact lens, which is the effect of the present invention, can be sufficiently obtained. Furthermore, good visibility and usability immediately after administration to the anterior segment can be obtained. Further, when producing the ophthalmic composition liquid of the present invention, good filterability is obtained, which is preferable.

  As a refreshing agent of the component C, L-menthol is mentioned, for example. The concentration of the refreshing agent in the ophthalmic composition liquid may be in a range that exhibits the effect of the present invention, but specifically, for example, it is preferably in the range of 1.0% by mass or less. Further, this concentration is preferably 0.0001% by mass or more, and more preferably 0.001% by mass or more. The concentration is more preferably 0.1% by mass or less. Within these concentration ranges, the effect of suppressing the change in the base curve of the contact lens, which is the effect of the present invention, can be sufficiently obtained. Furthermore, a good feeling of use and a refreshing refreshing feeling immediately after administration to the anterior ocular segment are obtained, which is preferable from the viewpoint of compliance (strict adherence to dosage regimen).

  The ophthalmic composition liquid of the present invention may contain other components different from the components A to C as long as the effects of the present invention are not impaired. As such a component, an active ingredient expected for a medicinal effect used in a known ophthalmic composition, an additive necessary for formulation design, or the like may be blended. Specifically, for example, known buffers, pH adjusters, surfactants, thickeners, tonicity agents, chelating agents, wetting agents, stabilizers, fragrances or cooling agents, drugs, antibacterial agents, preservatives -A disinfectant etc. may be mix | blended 1 type or in combination of 2 or more types. On the other hand, it is desirable not to add components that may impair the effects of medical devices such as contact lenses and intraocular lenses even in components and concentrations that are ophthalmically acceptable.

  Examples of the buffering agent include boric acid, borax and borate buffer, carbonate buffer, citric acid and citrate buffer, carboxylic acids such as acetic acid, acids such as oxycarboxylic acid and salts thereof Amino acids such as aminoethylsulfonic acid, aspartic acid (salt), glycine, arginine, glutamic acid, ε-aminocaproic acid, 2-amino-2-methyl-1,3-propane (AMP) buffer, tris (hydroxymethyl) ) Aminomethane (Tris) buffer, bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane (Bis-Tris), phosphoric acid and phosphate buffer, Good-Buffer and the like.

  Examples of the pH adjuster to be blended include hydrochloric acid, citric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, boric acid, borax, sodium hydrogen phosphate, sodium dihydrogen phosphate and the like. Examples thereof include phosphate and sulfuric acid.

As the surfactant, any of conventionally known anionic surfactants, nonionic surfactants, and amphoteric surfactants can be appropriately employed. Examples of such surfactants include polyglycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters (high purity polysorbates and polysorbates), polyoxyethylene alkylphenyl ether formaldehyde condensates, polyoxyethylene hydrogenated castor oil, polyoxyethylene Alkylphenyl ether, polyoxyethylene glycerin fatty acid ester, polyoxyethylene castor oil, polyoxyethylene sterol, polyoxyethylene hydrogenated sterol,
Polyoxyethylene fatty acid ester, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene lanolin alcohol, polyoxyethylene alkylamine, polyoxyethylene alkylamide, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl ether carboxylate, Polyoxyethylene alkyl ether sulfate, alkyl fatty acid salt, alkyl phosphate, N-acyl taurine salt, alkyl glutamate, alkyl glycine salt, alkyl alanine salt, cocoyl fatty acid arginine, alkyl sulfate, alkyl sulfonate, betaine acetate Type double-sided activator, alkyloxyhydroxypropyl arginine salt, cocoyl arginine ethyl PCA and the like.

  Examples of the thickener include polyethylene glycol, polypropylene glycol, polyacrylamide, polyvinyl alcohol (fully saponified product or partially saponified product), polyvinyl pyrrolidone, poly (meth) acrylic acid and salt, Polymer 845 (polyvinyl pyrrolidone and dimethylaminoethyl methacrylate). Synthetic organic polymer compounds such as copolymers) and cellulose derivatives such as methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose (hypromellose), carboxymethylcellulose, carboxyethylcellulose, and hydrophobized hydroxypropylmethylcellulose And starch derivatives, alginic acid (salt), Chin, chitosan, and their salts, polysaccharides chitosan derivatives such as cationized chitosan, and gellan gum heteropolysaccharide may be added mucopolysaccharides such chondroitin sulfate, etc. (salt).

  Examples of tonicity agents include inorganic salts such as sodium chloride, potassium chloride, sodium bisulfite, sodium sulfite, magnesium chloride, potassium acetate, sodium acetate, sodium thiosulfate, and magnesium sulfate, and polyhydric alcohols such as propylene glycol and glycerin. Alternatively, ethers or esters thereof may be mentioned.

  Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts thereof (ethylenediaminetetraacetic acid, disodium (EDTA, 2Na), ethylenediaminetetraacetic acid, trisodium (EDTA, 3Na), ethylenediaminetetraacetic acid, tetrasodium (EDTA, 4Na). Etc.), phytic acid, citric acid and the like.

Examples of the wetting agent include glycerin, propylene glycol, polyethylene glycol, polyoxyethylene castor oil, polypropylene glycol, xylitol, sorbitol, mannitol, erythritol, trehalose, glucose, sucrose, maltose, lactose and other polyhydric alcohols, sugars, and sugar alcohols. , Amino sugars such as glucosamine (salt), acetylglucosamine, galactosamine, acetylgalactosamine, sugar derivatives such as glucosyl trehalose, polyvinylpyrrolidone, poly (meth) acrylic acid and salts, copolymer 845 (copolymer of polyvinylpyrrolidone and dimethylaminoethyl methacrylate) ), Polyvinyl compounds such as 2-methacryloyloxyethyl phosphorylcholine, cationized cellulose, etc. Hydroxyethylcellulose, methylcellulose, hydroxypropylmethylcellulose (hypromellose), cellulose derivatives such as hydrophobized hydroxypropylmethylcellulose, lower or higher alcohols such as ethanol, isopropanol, oleyl alcohol, lauryl alcohol, almond oil, lanolin, olive oil, oleic acid and / or Or the salt, liquid paraffin, triglyceride, squalane, petrolatum, silicon oil, sesame oil, perilla oil, soybean oil, camellia oil, jojoba oil, corn oil, castor oil, etc. In addition, because it is safe for the eyes and reduces the influence on the contact lens, and further improves the usability of the contact lens composition, glycerin, propylene glycol, polyethylene glycol, polypropylene glycol, xylitol, Polyhydric alcohols such as sorbitol, mannitol, erythritol, trehalose, glucose, sucrose, maltose, lactose, sugar derivatives such as sugar, sugar alcohol, glucosyl trehalose, polyvinyl alcohol (fully saponified or partially saponified), polyvinylpyrrolidone, poly (meta ) Acrylic acid and salts, Copolymer 845 (copolymer of polyvinylpyrrolidone and dimethylaminoethyl methacrylate), 2-methacryloyloxyethyl Polyvinyl compounds such as Suhorirukorin, cationized cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, that cellulose derivatives such as methyl cellulose is selected preferably.

  Stabilizers include ascorbic acid, ascorbic acid glucoside, sodium edetate, cyclodextrin, condensed phosphoric acid, sulfite, citric acid, trometamol, sodium formaldehyde sulfoxylate (Longalite), cyanocobalamin, pyridoxine hydrochloride, tocopherol, sodium pyrosulfite , Monoethanolamine, aluminum monostearate and the like.

  Examples of the fragrance or refreshing agent include anethole, eugenol, camphor, chlorobutanol, geraniol, cineol, borneol, menthol, limonene, ryuuno, fennel oil, cool mint oil, cinnamon oil, spearmint oil, peppermint water, peppermint oil, peppermint Oil, bergamot oil, eucalyptus oil, rose oil and the like.

  Examples of the drug include antiallergic agents such as cromoglycic acid, chlorpheniramine maleate, diphenhydramine hydrochloride, amlexanox, ibudilast, pemirolast potassium, emedastine fumarate, ketotifen fumarate, olopatadine hydrochloride, ebastine, levocabastine, cetirizine hydrochloride, Glycyrrhizic acid and its salts, ε-aminocaproic acid, allantoin, sodium azulene sulfonate, berberine chloride, berberine sulfate, zinc sulfate, zinc lactate, lysozyme, fluorometholone and other steroidal or nonsteroidal anti-inflammatory agents, epinephrine, epinephrine hydrochloride , Ephedrine hydrochloride, naphazoline hydrochloride, naphazoline nitrate, phenylephrine hydrochloride, tetrahydrozoline hydrochloride, and other vasoconstrictors, methyl sulfate neostigmine, etc. Agents for improving the function of ant control, betaxolol, timolol, dipivefrin, carteolol, latanoplast, tafluplast, travoplast, nipradilol, levobunol, etc. Vitamins such as sodium adenine dinucleotide, cyanocobalamin, retinol acetate, retinol palmitate, pyridoxine hydrochloride, panthenol, calcium pantothenate, sodium pantothenate, tocopherol acetate, ascorbic acid, ascorbic acid glucoside, aspartic acid and its salts, aminoethyl Amino acids such as sulfonic acid, chondroitin sulfate, arginine, alanine, lysine, glutamic acid and the like can be mentioned.

  Antibacterial agents include, for example, sulfamethoxazole, sulfamethoxazole sodium, sulfisoxazole, sulfisomidine sodium and other sulfa drugs, ofloxacin, norfloxacin, levofloxacin, gatifloxacin, moxifloxacin, tosufloxacin New quinolone antibacterial agents such as lomefloxacin and ciprofloxacin, aminoglycoside antibacterial agents such as tobramycin, gentamicin, micronomycin, dibekacin and sisomycin, tetracycline antibacterial agents such as tetracycline and minocycline, and macrolide antibacterial agents such as erythromycin And chloramphenicol antibacterial agents such as chloramphenicol, and cephem antibacterial agents such as cefmenoxime.

Examples of preservatives and bactericides include sorbic acid, potassium sorbate, benzoic acid or salts thereof, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, chlorobutanol, benzalkonium chloride, Polyhexanide hydrochloride (polyhexamethylene biguanide; PHMB), alkyldiaminoethylglycine hydrochloride, cetylpyridinium chloride (CPC), chlorhexidine, alexidine, chlorpheniramine or salts thereof, allantoin, hydrogen peroxide, chlorine dioxide, stabilized chlorine dioxide, Examples thereof include polyquaterniums such as sodium chlorate, sodium perborate, and polydronium chloride. Among these, when considering the balance between storage efficacy and safety, and further considering application to contact lenses, potassium sorbate, polyhexanide hydrochloride (polyhexamethylene biguanide; PHMB), alkyldiaminoethylglycine hydrochloride, chlorhexidine, Sodium chlorite, hydrogen peroxide, sodium perborate, polydronium chloride and the like are more preferable.

  In addition, when the above preservatives are used, it is also possible to set it as 1 to 3 months as a standard of the expiration date after opening a product, for example. Specifically, polyhexanide hydrochloride (polyhexamethylene biguanide; PHMB) in the preparation is blended in the range of 0.5 ppm to 1.5 ppm, or boric acid in the range of 0.5% to 2.0%. By blending or satisfying these combinations, the expiration date after opening the product can be set to 1 to 3 months (including 1 to 2 months after opening and 2 to 3 months after opening). In addition, the method described in ISO 14730 (2000) is applied mutatis mutandis for setting the deadline after product opening, and the results of stability tests (for example, storage at 40 ° C. ± 1 ° C., 75% RH ± 5% for a predetermined period) Therefore, it is possible to judge the antibacterial contamination resistance after opening. On the other hand, the ophthalmic composition liquid according to the present embodiment can be free of so-called preservatives without adding a preservative. In the case of preservative-free, in addition to the usual multi-dose type, a single-dose type that can be used once (one dose may be given to one eye or one dose to both eyes may be given once) ), Multi-dose type that can be used multiple times, or multi-dose type that uses a discharge container with a filter that can maintain sterility so that bacteria do not grow in the composition, etc. It can be selected appropriately. In addition, in the case of a single use, the deadline after opening the product is not set, and it is discarded immediately after use.

  It is preferable that the container conforms to the standard and test method of the eye drop plastic container (Notification of Drug Development No. 336) dated March 28, 1996, and the material is polyethylene, polypropylene, polyethylene terephthalate, Polycarbonate, polystyrene, acrylonitrile-styrene copolymer and the like are selected. Examples of the method for forming the container include injection molding, direct blow molding, biaxial stretch blow molding, tube molding, thermoforming molding, and blow fill seal. The container body (bottle) is more preferably selected from injection molding, direct blow molding, biaxial stretch blow molding, and blow fill seal, which are excellent in moldability, molding accuracy, and confidentiality.

On the other hand, when the ophthalmic composition liquid according to the present invention is applied as a contact lens liquid, the component (component D) selected from the following is optionally appropriately blended as long as the effects of the present invention are not impaired. By doing so, the refractive index of the contact lens can be increased when the contact lens is worn (when applied before wearing the contact lens, when applied while wearing the contact lens). In other words, it becomes possible to obtain a clearer view through the contact lens. Preferred components as component D include aromatics and inorganic salts, for example. Preferred aromatics include tetrahydrozoline hydrochloride, naphazoline, neostigmine methyl sulfate, berberine, sodium azulene sulfonate, chlorpheniramine maleate. Ketotifen fumarate, sodium flavin adenine dinucleotide, cyanocobalamin, pyridoxine hydrochloride, tocopherol acetate, sulfamethoxazole, latanoprost, nipradilol, rebamipide, benzalkonium chloride, benzethonium chloride and the like. Preferred inorganic salts include sodium chloride, boric acid, zinc sulfate, zinc lactate, calcium chloride and the like, and the above aromatic components and the like according to necessity such as expected pharmacological action and degree of improvement in contact lens refractive index. At least one selected from inorganic salt components is blended. In addition, the component D in the ophthalmic composition liquid according to the present invention may be blended as a component that improves the refractive index of the contact lens, or may be blended in expectation of the pharmacological action of the component D. Regardless of the reason for blending component D, the ophthalmic composition liquid containing component D only needs to improve the refractive index of the contact lens as a result.

  Among these, for aromatics, the blending amount can be ranged depending on the number of aromatic rings in the molecule. Specifically, in the case of one aromatic ring in the molecule, in the range of 0.001% by mass to 0.2% by mass, and in the case where two or more aromatic rings exist in the molecule, 0.0005% by mass. % To 0.1% by mass or less is preferable. On the other hand, among inorganic salts, sodium chloride and boric acid can be particularly preferably used. Therefore, only when these are blended, 0.4% by mass or more is blended as at least one concentration selected from these. More preferably. However, it is not preferable to increase the refractive index of the contact lens even if it is transient, that is, to produce an overcorrected state. Sodium chloride and boric acid are each 2% by mass. Should be blended up to the upper limit.

  When the ophthalmic composition liquid according to the present invention in which these are blended is applied as a contact lens liquid, the refractive index of the contact lens is temporarily improved when it comes into contact with the contact lens. In addition to the components A to C and the component D, the contact lens is further improved in the refractive index of the contact lens. Further, the surface of the contact lens (front surface, rear surface, or both front and rear curved surfaces). In addition, a method for obtaining a clear field of view through such a contact lens by contacting the liquid to be used is also included.

  Furthermore, when the components contained in the ophthalmic composition liquid or the ophthalmic composition liquid according to the present invention are present in the contact lens or on the surface of the contact lens, the contact lens refractive index is improved. On the other hand, the components contained in the ophthalmic composition liquid or ophthalmic composition liquid according to the present invention are diluted with time by lacrimation. The time during which the refractive index of the contact lens is improved is temporary, but the components A to C in the present invention control the amount of component D taken into and released from the contact lens, and the residence time on the contact lens surface. It also serves as a Therefore, one of the aspects of the ophthalmic composition liquid according to the present invention includes a method for controlling the uptake / release of the component D from the contact lens and the residence time on the contact lens surface as described above. .

  In particular, the time during which the refractive index of the contact lens is improved does not have to be long, but rather needs to be short in order to avoid overcorrection. Specifically, the time during which the components contained in the ophthalmic composition liquid or the ophthalmic composition liquid according to the present invention are in contact with the contact lens in the anterior segment should be limited to, for example, 60 minutes or less. It is.

The refractive index can be measured by a general measurement method according to JIS K0062. And the following method is employ | adopted about the improvement effect of a refractive index. That is, after immersing the contact lens in the ophthalmic composition liquid according to the present invention and Japanese Pharmacopoeia purified water (hereinafter referred to as purified water) for 4 hours, the contact lens (1T manufactured by Atago Co., Ltd.) was used. The refractive index (sodium-D line) at 20 ° C. of a contact lens having a vertex refractive power of −0.50 D is measured. The refractive index improvement rate (%) can be obtained using Equation 1 with respect to the measured value of the contact lens after being treated with the ophthalmic composition liquid and purified water of the present invention. In the present invention, the refractive index improvement rate is preferably 0.5% to 15%, more preferably 2.5% to 10%.
[Formula 1]
Refractive index improvement rate (%) = ({(refractive index when using the ophthalmic composition liquid of the present invention) / (refractive index when using purified water)}-1) × 100

  The ophthalmic composition solution of the present invention is evaluated for safety in a cytotoxicity test as described in ISO10993-5, for example, at a concentration (IC50) when the colony formation inhibition rate is 50% compared to the control. Be evaluated. The ophthalmic composition liquid of the present invention has an IC50 value of 1.0% or more, more preferably 2.0% or more. An IC50 value of 1.0% or more is preferable because it has lower cytotoxicity and higher safety. In addition, when using the raw material poloxamers containing BHT for the ophthalmic composition liquid of this invention, the BHT density | concentration in a formulation should be restrict | limited to the range of 0.001 ppm or more and 0.7 ppm or less.

  In the ophthalmic composition liquid of the present invention, the concentration of BHT is less than 1.5 ppm. In this range, the safety is higher. The concentration of BHT is preferably 1.0 ppm or less, more preferably 0.7 ppm or less, and even more preferably BHT is not included. In addition, when the raw material poloxamers containing BHT are used for the ophthalmic composition liquid of the present invention as necessary, the BHT concentration in the preparation should be limited to a range of 0.001 ppm to 0.7 ppm. This is because the presence of BHT in the preparation at as low a concentration as possible further increases safety as an ophthalmic composition liquid and in contact lens wearing.

The ophthalmic composition liquid of the present invention can be used for various known contact lenses. Specifically, hard contact lenses, soft (hydrogel) contact lenses, non-vision correction soft (hydrogel) contact lenses, and the like are included. Non-sight correction software (hydrogel) contact lenses include "changing the appearance (color, pattern, shape) of the iris or pupil" in the effects and effects of contact lenses. "Soft contact lens". This soft contact lens contains dyes and pigments (also referred to as pigments) for the purpose of changing the appearance, but those that are exposed to the contact lens surface or pigments contact Including a lens polymer layer (so-called sandwich structure). Among these, in the combined use with the ophthalmic composition liquid of the present invention, the contact lens having a pigment preferably has a sandwich structure. In addition, contact lenses include hydrogel materials classified as groups I to V in ISO 18369-1 (2006 and Amendment 1, 2009), and non-hydrogel materials classified as groups I to IV. (Non-hydrogen materials) are also included. The hard contact lens also includes a non-oxygen permeable hard contact lens mainly composed of polymethyl methacrylate, and an oxygen permeable hard contact lens (RGP) containing silicon or fluorine and imparting oxygen permeability. Furthermore, contact lenses also include therapeutic contact lenses used for eye protection, anterior chamber sealing, drug delivery, corneal curvature change, retinal treatment, and the like. In the present invention, among these hard contact lenses, the non-hydrogen materials group III lens described in ISO 18369-1 (2006), that is, a hard contact lens containing both a silicone component and a fluorine component is preferable.

The ophthalmic composition liquid of the present invention may be used for a hard contact lens manufactured by cutting / polishing for use as a contact lens liquid, in particular, a hard contact manufactured by a mold manufacturing method. More preferred for use with lenses. Furthermore, with regard to the use of hard contact lenses manufactured by a mold manufacturing method, disposable types such as one-day disposables are prohibited from being reused, and less than one year is used for one month to several months. Is a frequent exchange type that is exchanged, a regular exchange type that is used over a period of 1 month to 1 week, and is exchanged after that period, and a conventional type that is used over a period of one year. The hard contact lens may be used. As for the hard contact lens manufactured by the mold manufacturing method, the entire surface or a part of the lens surface such as a double-sided mold, a single-sided mold, and a half-sided mold may be used. Furthermore, the surface treatment may be performed after the production. For example, any surface treatment such as surface graft polymerization, IPN (Interpenetrating Polymer Network), or plasma treatment may be selected. Of course, the surface treatment may not be performed.

  As a contact lens in which the ophthalmic composition liquid of the present invention is used, it is used for eye protection, anterior chamber blocking, drug delivery, corneal curvature change (including orthokeratology contact lenses), retina treatment, etc. Therapeutic contact lenses and test contact lenses, diagnostic contact lenses for diagnosing diseases from tear fluid components, sunglasses contact lenses with functions such as amplification and reduction of visual field contrast, reduction of incident light, polarization, and dimming Also included is a monitor contact lens that projects an image onto the retina.

  For soft contact lens materials, ionic, non-ionic, surface zeta potential, moisture content, presence / absence of surface treatment (examples of surface treatment are for example by surface graft polymerization, by plasma treatment, by IPN), Distribution stock solutions (such as those containing a moisturizing agent or a surface active component that shows a moisturizing effect on physiological saline or lenses), ion permeability coefficient, oxygen permeability coefficient, Young's modulus, refractive index, Various contact lens materials are proposed including physical properties such as surface friction coefficient, and these manufacturing methods, including lace-cut method, mold method (static mold method, spin cast method, surface multilayer mold method), injection molding, etc. However, the ophthalmic composition liquid of the present invention can be applied to all soft contact lenses. . In addition, it is also possible to select a contact lens material that is particularly preferable from the viewpoints of functions and commerce from these various contact lenses described above, and apply the contact lens liquid of the present invention.

  Concerning the shape of contact lenses, there are two or more types of materials, including corneal contact lenses, semi-scleral contact lenses, scleral contact lenses, and hybrid contact lenses (contact lenses that combine oxygen-permeable hard contact lenses and soft contact lenses). It may be a contact lens). Any contact lens design may be used, such as for astigmatism, for farsightedness, for astigmatism, for both near and near, and for shortsightedness. The contact lens may be a disposable contact lens that is used only for a short period such as one day or one week to several months, or may be a normal contact lens that is used for a longer period of time. Good.

The ophthalmic composition liquid of the present invention includes "general eye drops", "antibacterial eye drops", "artificial tears", "contact lens mounting liquids", "contact lens mounting drugs", and further, "contact lens cleaning agents", " Contact lens preservatives, “contact lens cleaning preservatives”, “contact lens rinsing liquids”, liquids that immerse contact lenses in the distribution of contact lenses (packaging liquids), and hard contact lens disinfectants Can do. Examples of the soft contact lens agent include a soft contact lens disinfectant and a soft contact lens multipurpose liquid agent. That is, it can be used as a liquid that comes into contact with the contact lens before, during, or after wearing the contact lens. In addition, this ophthalmic composition liquid is not only a contact lens wearing medicine, but also a so-called “contact lens wearing / ophthalmic solution” which can be instilled with the same prescription preparation, and a contact lens distribution storage solution and a contact lens wearing medicine. , "Contact Lens Rinsing Solution" and "Contact Lens Wearing Solution (Contact Lens Wearing Drug)", "Contact Lens Multipurpose Liquid (Washing / Rinsing / Disinfection / Storage)" and "Contact Lens Wearing" It is also possible to apply “liquid” and “ophthalmic solution” in one liquid (same formulation). In this way, by having a multipurpose function as a contact lens solution, conventionally, the interaction between the preparations due to the retention of the preparation in the conjunctival sac such as “it should be instilled after use of the contact lens wearing medicine” This is also useful from the viewpoint of preventing misuse. Although specifically shown in the examples described later, the contact lens solution of the present invention suppresses changes in the base curve during the use of hard contact lenses and soft contact lenses, and also exhibits a significant antifouling effect. It is also useful as a liquid used when it is necessary to correct vision with a contact lens after LASIK (Laser assisted in Situ Keratomileusis).

  For example, the pH value of the ophthalmic composition liquid of the present invention is preferably in the range of 3.0 to 9.0, more preferably in the range of 5.0 to 8.5. The osmotic pressure is in the range of 100 mOsm / kg to 900 mOsm / kg, more preferably in the range of 150 mOsm / kg to 500 mOsm / kg.

  Since the ophthalmic composition liquid of the present invention can suppress the base curve change of the hard contact lens manufactured by the mold manufacturing method, and further can suppress the base curve change during the wearing period of the soft contact lens, the efficiency In order to obtain these effects well, a method of using the contact lens is preferable, but it is more preferable to contact the back curved surface (base curve surface) of the contact lens. Regarding the use of the ophthalmic composition liquid of the present invention, the contact lens is worn after being dropped on the base curve surface of the contact lens before wearing, or the ophthalmic composition liquid of the present invention is 1 to 3 while wearing the contact lens. Applying a drop and blinking several times, holding the eye gently for a while (for example, within 3 minutes) after closing, or closing the eye for a while after applying, the front curved surface of the wearing contact lens (front curve surface) In addition, there is a method of spreading the liquid over the base curve surface. These post-instillation methods are not only used personally, but lead to a more comfortable use of contact lenses. In other words, from the viewpoint of the contact lens industry, it goes without saying that these methods of use contribute to the development of the industry and can be used as a business. In addition, when administering the ophthalmic composition liquid of the present invention to the anterior ocular segment, it is sufficient if there is a capacity accommodated in the conjunctival sac, but in particular, the drop volume dropped from the container is 0.005 mL to 0.05 mL. It is said.

  The ophthalmic composition liquid of the present invention is a polyoxyethylene polymer in which the ratio EO / PO between the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is 1.0 or more and 5.0 or less. Polyoxypropylene glycol, one or more selected from polyvalent carboxylic acids and polyvalent carboxylates, and a cooling agent, having an IC50 value of 1.0% or more, and dibutylhydroxytoluene (BHT) An ophthalmic composition liquid having a concentration of less than 1.5 ppm is used for a hard contact lens and / or a soft contact lens manufactured by a mold manufacturing method. In this method of use, it may be used for the contact lens described above, and among them, it can be used for a hard contact lens manufactured by a mold manufacturing method to further improve the feeling of use and wear of the contact lens. That is, by using the ophthalmic composition liquid of the present invention, an effect on discomfort when wearing a contact lens can be obtained. On the other hand, it can be suitably used for soft contact lenses. Among them, the base curve change during wearing of these contact lenses is applied to soft contact lens classification groups IV and V defined in ISO18369-1. It is more preferable because it can be effectively suppressed or the refractive index of the contact lens can be effectively improved.

The ophthalmic composition liquid and the method of using the ophthalmic composition according to this embodiment described in detail above can further improve the feeling of use and safety with respect to the use for contact lenses. For example, since the change of the base curve of the contact lens can be further suppressed by containing the components A to C, the feeling of use and wearing of the contact lens can be further improved. Moreover, since the lipid adhesion amount to a contact lens can be suppressed more by containing component AC, for example, a usability | use_condition can be improved more. IC50 value is 1.0
%, And since the BHT concentration is less than 1.5 ppm, the safety is further improved. Further, by further blending component D, the refractive index of the contact lens can be improved, and the feeling of use and wearing of the contact lens can be further enhanced.

  It should be noted that the present invention is not limited to the above-described embodiment, and it goes without saying that the present invention can be implemented in various modes as long as it belongs to the technical scope of the present invention.

  Below, the example which specifically produced and used the ophthalmic composition liquid of this invention is demonstrated as an experiment example. Experimental Examples 1 to 12, 19 to 30, 34 to 45, 59 to 66, 77 to 88, 102 to 111, 116, 117, and 120 to 130 correspond to Examples of the present invention, and Experimental Examples 13 to 18 31 to 33, 46 to 58, 67 to 76, 89 to 101, 112 to 115, 118, 119, and 131 to 133 correspond to comparative examples.

[Ophthalmic Composition Solution of Experimental Examples 1 to 58]
Each compound was mixed by the composition as shown in Tables 1-6, and it was set as the composition liquid. As polyvalent carboxylic acid or salt, sodium edetate hydrate, citric acid hydrate, sodium hyaluronate, carboxyvinyl polymer (Hibiskowa 105 manufactured by Wako Pure Chemical Industries, Ltd.) was used. Further, as polyoxyethylene-polyoxypropylene glycol, a poloxamer 407 (average molecular weight 12600, co-polymer) having a ratio EO / PO of 2.93 between the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide. Polymer A) was used. Further, as the copolymer, poloxamer 403 (average molecular weight 5750, copolymer B) having a ratio EO / PO of 0.63, and Pluronic L-44 (average molecular weight 2200, copolymer having a ratio EO / PO of 1.0). Polymer C), Unilube 70DP-950B (copolymer D) with a ratio EO / PO of 2.86, Pluronic F-87 with a ratio EO / PO of 4.0 (average molecular weight 7700, copolymer E) Pluronic F-68 (average molecular weight 8400, copolymer F) having a ratio EO / PO of 5.3 was used. In addition, L-menthol and other ingredients such as boric acid, sodium chloride, polyhexanide hydrochloride, pH adjuster (sodium hydroxide / dilute hydrochloric acid) and purified water were added to obtain a composition solution having a pH of 7.3 and a total amount of 100 mL. It was.

[Production of hard contact lenses]
The test lens (1) was produced as follows. The raw materials were blended in 60 parts by weight of tris (trimethylsiloxy) silylpropyl methacrylate, 30 parts by weight of trifluoroisopropyl methacrylate, 10 parts by weight of methyl methacrylate, 5 parts by weight of ethylene glycol dimethacrylate, 2,2-azobis (2 , 4-dimethylvaleronitrile) was 0.05 parts by mass. This monomer mixture was thermally polymerized in a test tube by a known method. The obtained bulk polymer was cut and polished by a lathe and processed into a lens of base curve (BC) /Power/Dia=7.80 mm / −7.00 D / 9.2 mm (cutting polishing processing, surface treatment) None).

  The test lens (2) was produced as follows. The raw materials were blended in 60 parts by weight of tris (trimethylsiloxy) silylpropyl methacrylate, 30 parts by weight of trifluoroisopropyl methacrylate, 10 parts by weight of methyl methacrylate, 5 parts by weight of ethylene glycol dimethacrylate, 2,2-azobis (2 , 4-dimethylvaleronitrile) was 0.05 parts by mass. This monomer mixture was polymerized by a known method in a polypropylene cast mold and formed into a lens of BC / Power / Dia = 7.80 mm / −7.00 D / 9.2 mm (no mold manufacturing method, no surface treatment) ).

The test lens (3) was produced as follows. The raw materials were blended in 40 parts by weight of tris (trimethylsiloxy) silylstyrene, 40 parts by weight of hexafluoroisopropyl methacrylate, 10 parts by weight of methyl methacrylate, 5 parts by weight of ethylene glycol dimethacrylate, 5 parts by weight of vinylbenzyl methacrylate, The amount of 2,2-azobis (2,4-dimethylvaleronitrile) was 0.05 parts by mass. This monomer mixture was thermally polymerized in a test tube by a known method. The obtained bulk polymer was cut and polished into a lens shape with a lathe, and then the polymer was subjected to plasma treatment (RF output 50 W, 100 Pa) in an oxygen atmosphere, and BC / Power / Dia = 7.80 mm / -It processed into the lens of 7.00D / 9.2mm (with cutting polishing process and surface treatment).

  The test lens (4) was produced as follows. The raw materials were blended in 40 parts by weight of tris (trimethylsiloxy) silylstyrene, 40 parts by weight of hexafluoroisopropyl methacrylate, 10 parts by weight of methyl methacrylate, 5 parts by weight of ethylene glycol dimethacrylate, 5 parts by weight of vinylbenzyl methacrylate, The amount of 2,2-azobis (2,4-dimethylvaleronitrile) was 0.05 parts by mass. A lens-shaped polymer is prepared from this monomer mixture by a known method using a cast mold made of polypropylene, and then the polymer is subjected to plasma treatment (RF output 50 W, 100 Pa) in an oxygen atmosphere. The lens was molded into a lens of Power / Dia = 7.80 mm / −7.00 D / 9.2 mm (with mold manufacturing method and surface treatment).

(Measurement of hard contact lens base curve)
The base curve (back surface radius of curvature) for the test lens shown below was measured in a constant temperature environment of 20 ± 5 ° C. using a contact gauge CGX manufactured by Knights. The test lens was immersed in a physiological saline solution (ISO saline) prescribed in advance in ISO 18369-3 (2006) for 8 hours or more at a temperature of 20 ± 5 ° C. After a predetermined immersion time, the base curve was measured to the unit of 0.01 mm as an initial value. Thereafter, the hard contact lens was taken out and immersed in the composition solution at a temperature of 20 ± 5 ° C. for 8 hours. After a predetermined time, the base curve was measured to a unit of 0.01 mm as a measured value. Ten hard contact lenses used for the test were used for each composition liquid, and the average was determined in units of 0.01 mm. From the average of the initial values (BCs) and the average of the measured values (BCm), the rate of change of the base curve (BC) is obtained using the following equation (1), and the base curve is obtained from the value according to the equation (2). The index of the effect of suppressing change was obtained.
BC change rate (%) = (BCs−BCm) / BCs) × 100 (1)
Inhibitory effect index = 100 × [α (%) − BC change rate (%)] / α (%) (2)
However, α is a base curve change rate (%) in a formulation in which the same copolymer is blended in the same blending amount and does not include a polyvalent carboxylic acid component. That is, the inhibitory effect index is the change suppression score when the BC change suppression caused by poloxamer and menthol is 0 points and the score of ISO raw food is 100 points. That is, in the test lens (1), in Tables 1 and 2, in the experimental example 1 and the experimental example 13, the BC change rate (3.21) of the experimental example 13 and the BC change rate (1.52) of the experimental example 1 Therefore, the suppression effect index of Experimental Example 1 can be obtained by (3.21−1.52) /3.21×100.

(Measurement results and discussion of BC change rate and inhibition effect index)
The measurement results are shown in Tables 1-6. As shown in Tables 1 to 6, in a composition liquid containing a poloxamer having an EO / PO in the range of 1.0 to 5.0, a polyvalent carboxylic acid or a salt thereof, and L-menthol, BC change The rate was smaller and the inhibition effect index tended to be higher. On the other hand, the composition liquid not containing one or more of these three components tended to have a large BC change rate. Further, it was found that the hard contact lens that was molded had a smaller BC change rate and a higher suppression effect index than the hard contact lens that had been machined. That is, a composition liquid containing a poloxamer having an EO / PO in the range of 1.0 to 5.0, a polyvalent carboxylic acid or a salt thereof, and L-menthol is used for a molded hard contact lens. Was found to be more preferable.

[Ophthalmic Composition Solution of Experimental Examples 59 to 101]
Each compound was mixed by the composition as shown in Tables 7-10, and it was set as the composition liquid. As polyvalent carboxylic acid or salt, sodium edetate hydrate, citric acid hydrate, sodium hyaluronate, carboxyvinyl polymer was used. Further, as polyoxyethylene-polyoxypropylene glycol, copolymer A (EO / PO = 2.93), copolymer B (EO / PO = 0.62), copolymer C (EO / PO = 1) 0.0), copolymer D (EO / PO = 2.86), copolymer E (EO / PO = 4.0), copolymer F (EO / PO = 5.3), and the like. In addition, L-menthol and other ingredients such as boric acid, sodium chloride, polyhexanide hydrochloride, pH adjuster (sodium hydroxide / dilute hydrochloric acid) and purified water were added to obtain a composition solution having a pH of 7.3 and a total amount of 100 mL. It was.

[Production of hard contact lenses]
The test lens plate (X) was produced as follows. The raw materials were blended in 60 parts by weight of tris (trimethylsiloxy) silylpropyl methacrylate, 30 parts by weight of hexafluoroisopropyl methacrylate, 10 parts by weight of methyl methacrylate, 5 parts by weight of ethylene glycol dimethacrylate, 2,2-azobis (2 , 4-dimethylvaleronitrile) was 0.05 parts by mass. This monomer mixture was thermally polymerized in a test tube by a known method. The obtained bar was cut and polished with a lathe to produce a plate having a diameter of 20 mm and a thickness t = 0.2 mm, which was used as a test lens plate (X).

  The test lens plate (Y) was produced as follows. The raw materials were blended in 60 parts by weight of tris (trimethylsiloxy) silylpropyl methacrylate, 30 parts by weight of hexafluoroisopropyl methacrylate, 10 parts by weight of methyl methacrylate, 5 parts by weight of ethylene glycol dimethacrylate, 2,2-azobis (2 , 4-dimethylvaleronitrile) was 0.05 parts by mass. This monomer mixture was thermally polymerized by a known method so as to form a plate having a diameter of 20 mm and a thickness t = 0.2 mm in a polypropylene cast mold, and this was used as a test lens plate (Y).

(Lipid adhesion inhibitory effect test)
The test of the lipid adhesion inhibitory effect was performed by the Japanese Journal of Contact Lenses 37, p. 58, (1995). That is, for each of the test lens plate (X) and the test lens plate (Y), after wetting both surfaces of the lens with a few drops of each composition solution, it is placed in a glass vial containing 2.0 mL of artificial eye grease. Moved. The vial was allowed to stand at a constant temperature of 37 ° C. for 5 hours. Thereafter, each lens was taken out, rinsed with distilled water, and dried. The dried test lens was immersed in 1 mL of a mixed solution of ethanol: diethyl ether = 3: 1 for 10 minutes to obtain an extract. The total lipid content of this extract was quantified by the sulfuric acid / phosphoric acid / vanillin method described in the above literature. The lipid adhesion inhibitory effect was calculated | required by the following formula | equation using the quantitative value when using an ISO raw meal as a composition liquid as control. For each composition liquid, five experiments were performed using five lenses, and the average value was defined as a lipid adhesion inhibitory effect.
Lipid adhesion inhibitory effect (%) = 100 × {1− (quantitative result of sample (mg / cm ² ) / quantitative result of control (mg / cm ² ))}

(Measurement results and discussion of lipid adhesion inhibition effect)
The measurement results are shown in Tables 7-10. As shown in Tables 7 to 10, in the composition liquid containing a poloxamer having an EO / PO in the range of 1.0 to 5.0, a polycarboxylic acid or a salt thereof, and L-menthol, total lipids The amount of adhesion was small and the effect of inhibiting lipid adhesion tended to be higher. On the other hand, the composition liquid not containing one or more of these three components tended to have a large amount of lipid adhesion. In addition, the lipid adhesion suppression effect when using the composition liquid due to the difference in the manufacturing method of the contact lens, that is, the difference between the cutting / polishing (X) and the molding (Y), was obtained particularly by molding. It was confirmed that the lipid adhesion inhibitory effect on contact lenses was higher. That is, a composition liquid containing a poloxamer having an EO / PO in the range of 1.0 to 5.0, a polyvalent carboxylic acid or a salt thereof, and L-menthol is used for a molded hard contact lens. Was found to be more preferable.

[Ophthalmic Composition Solution of Experimental Examples 102 to 115]
Each compound was mixed with the composition as shown in Table 11 to obtain a composition solution. As polyvalent carboxylic acid or salt, sodium edetate hydrate, citric acid hydrate, sodium hyaluronate, carboxyvinyl polymer was used. Further, as polyoxyethylene-polyoxypropylene glycol, copolymer A (EO / PO = 2.93, BHT-free blend), copolymer A containing 100 ppm of dibutylhydroxytoluene (BHT), copolymer B (EO /PO=0.62) and copolymer D (EO / PO = 2.86) were used. In addition, L-menthol and other components such as d-camphor, boric acid, polyoxyethylene hydrogenated castor oil (HCO-60), polysorbate 80, sodium chloride, potassium chloride, aminoethylsulfonic acid, propylene glycol, glucose, hypromellose , Hydroxylethylcellulose, BHT, potassium sorbate, benzalkonium chloride, polyhexanide hydrochloride, pH adjuster (sodium hydroxide / dilute hydrochloric acid) and purified water are added, pH is 6.8-7.4, total volume is 100 mL A composition liquid was obtained.

(Colony formation inhibition test-cytotoxicity test)
With reference to ISO10993-5, a colony formation inhibition test using Chinese hamster lung (V79) cells was performed. That is, Chinese hamster lung cells (hereinafter referred to as V79) are grown in a tissue culture flask, treated with a 0.05% trypsin-EDTA solution to remove V79 from the flask, and 9.39 g of MO medium (Minimum Essential Medium) is removed. It melt | dissolved in 950 mL ultrapure water, and dispensed 190 mL at a time to a 200 mL bottle. Thereafter, this was autoclaved at 121 ° C. for 15 minutes, 6 mL of 7.5 w / v% sodium bicarbonate solution, 2 mL of 200 mM L-glutamine solution, 2 mL of 10 mM MEM non-essential amino acid solution, 100 mM pyruvin per bottle. 2 mL of sodium acid solution and 10 mL of fetal bovine serum were added and suspended in the prepared medium (hereinafter simply referred to as “medium”) to prepare a cell suspension of 5 × 10 2 cells / ml. Place 0.1 mL (12 wells) of this cell suspension in a tissue culture plate containing 1 mL of medium and leave it in a CO ₂ incubator (37 ° C., 5% CO ₂ , saturated steam). After culturing for a time, V79 was adhered to the bottom of the well. Remove the medium in the cell suspension and newly add 0.9 ml of medium (1.0 ml of medium is added for non-treatment (control)), and 0.1 mL of the composition diluted appropriately for IC50 calculation Additional (that is, the composition solution was added at a maximum of 10 v / v%) and cultured in a CO ₂ incubator for 6 days. After completion of the culture, the cells were washed with a phosphate buffer and methanol, the cells were fixed in the wells, the cells were stained with Giemsa staining solution, and the number of colonies was counted. And the density | concentration (IC50) when inhibiting 50% of colony formation was computed compared with the colony number of control.

(Cytotoxicity test-IC50 measurement results and discussion)
Table 11 shows the measurement results. As shown in Table 11, a composition containing polyoxyethylene-polyoxypropylene glycol having EO / PO in the range of 1.0 to 5.0, polycarboxylic acid or a salt thereof, and L-menthol. It was found that the liquid had an IC50 of 2.0% or more and low cytotoxicity. On the other hand, the composition liquid not containing one or more of these three components tended to have high cytotoxicity. In addition, the cytotoxicity also depends on the BHT concentration of the composition solution. When the BHT concentration satisfies 0.7 ppm or less, the IC50 is 2.0% or more, and it was found that the cytotoxicity is low. In contrast, in Experimental Example 111 where the BHT concentration in the preparation was substantially 1.0 ppm, the IC50 was in the range of 1.0% or more and less than 2.0%. Further, in Experimental Example 114 and Experimental Example 115 in which the BHT concentration in the preparation was 1.5 ppm, the IC50 was less than 1.0%, indicating that the cytotoxicity was higher.

[Ophthalmic Composition Solution of Experimental Examples 116 to 119]
Each compound was mixed with the composition as shown in Table 12 to obtain a composition solution. As polyvalent carboxylic acid or salt, sodium edetate hydrate and sodium hyaluronate were used. Further, as polyoxyethylene-polyoxypropylene glycol, copolymer A (EO / PO = 2.93), copolymer B (EO / PO = 0.62), copolymer D (EO / PO = 2) .86) was used. In addition, L-menthol and other components such as boric acid, polyoxyethylene hydrogenated castor oil (HCO-60), sodium chloride, potassium chloride, hypromellose, polyhexanide hydrochloride, pH regulator (sodium hydroxide / dilute hydrochloric acid), purified water Was added to obtain a composition solution having a pH of 7.3 and a total amount of 100 mL.

(Measurement of soft contact lens base curve)
With reference to ISO18369-3: 2006, using a soft contact lens analyzer (JCF type manufactured by Optimec Co., Ltd.), a base curve in a state where the soft contact lens is immersed in an ISO raw food maintained at 20 ° C. ± 1 ° C. Was measured.

(Soft contact lens wearing test)
Inviting healthy volunteers who regularly use contact lenses, 10 eyes and 20 eyes (6 males, 4 females average age 34.2 years old) and any of the ophthalmic composition liquids of Experimental Examples 116 to 119 in the case of eye drops Applied 6 times a day for 14 days in total while wearing contact lenses. Then, he was instructed to lightly hold the eyes while keeping his eyes closed for a while (within 3 minutes) after instillation. For daily disinfection and care of contact lenses, use a disinfection system with hydrogen peroxide (AOcept: manufactured by Ciba Vision) to avoid the effects of care product components on contact lenses as much as possible, and rinsing during wearing is autoclaved. ISO raw food was used. For contact lenses, wear either of the following two-week wear type soft contact lenses A and B on both eyes, and contact lens standards are the same for all wearers. Corrected with glasses. Wearing instructions were given so that the average daily wearing time was about 13 hours.

  The soft contact lens was opened, and in order to avoid the influence of the distribution stock solution, the base curve was measured by the above method and recorded in advance by immersing in an ISO raw food. Thereafter, the soft contact lens was rinsed with ISO raw food and then worn. The contact lens after wearing for 2 weeks (14 days) was collected and immersed in an ISO raw food temporarily (maximum 4 hours), and then a base curve measurement was performed promptly. The soft contact lens A was 2 week menicon premio (manufactured by Menicon Co., Ltd., non-ionic, asmofilcon A, group V, BC: 8.6 mm, Power: −3.00 D, Dia: 14.0 mm). In addition, the soft contact lens B is a one-day accur fine (manufactured by Johnson & Johnson Co., Ltd., ionic, etaficon A, group IV, natural shine, BC: 8.5 mm, Power: -3.00D, Dia: 14. 2 mm; soft contact lens for fashion, sandwich structure). As a control period, the wearer was allowed to use the contact lens for 2 weeks, and during the wear, guidance was given to prohibit the use of contact lens mounting solution or eye drops. After 14 days, the worn contact lenses were collected, and the base curve was measured according to the above method to determine the difference between before and after wearing. As for the use of each test liquid, with regard to Experimental Examples 116 and 117 and Experimental Examples 118 and 119, a predetermined composition liquid for 14 days with the one eye of the wearer as Experimental Example 116 or 117 and the other eye as Experimental Example 118 or 119 Was used. Note that Experimental Example 116 and Experimental Example 118 were evaluated as both a contact lens mounting solution and eye drops. That is, as a contact lens wearing / ophthalmic solution, (1) dripping directly onto the contact lens when wearing the contact lens, wetting both or one side of the contact lens, (2) wearing the contact lens on the eye, and (3) the contact In addition, it was also used by instilling while wearing the lens.

(Measurement results and consideration of wearing test considerations)
Table 13 shows the measurement results. As shown in Table 13, in the control without using eye drops, the base curves of both lenses showed a decrease of 0.12 to 0.16. When the composition liquids of Experimental Examples 116 and 117 were applied as eye drops while wearing contact lenses, the base curves after wearing could be suppressed to a decrease of 0.04 to 0.07 for both contact lenses A and B. That is, in a composition liquid containing a poloxamer having an EO / PO in the range of 1.0 to 5.0, a polycarboxylic acid or a salt thereof, and L-menthol, the change in the base curve after wearing is small. It was found preferable. On the other hand, in Experimental Example 118 that does not include a polyvalent carboxylic acid or a salt thereof, and in Experimental Example 119 using a poloxamer having an EO / PO of less than 1.0, the change in the base curve after wearing was large. Further, in Experimental Example 116 used as a wearing agent and an eye drop, the decrease in the base curves of both contact lenses could be significantly suppressed (0.01 to 0.02). In the control group, contact lens wear reduces the base curve of the contact lens used for wearing, and there are various factors such as the interaction between the contact lens and some components in tear fluid, and the effect of fitting. Although possible, details as the cause are unknown.

[Refractive index improvement function test]
Test for contact lens, the ring down Day Acuvue di Fine (Johnson & Johnson Co., Ltd., ionic, etafilcon A, Group IV, natural Shine, BC: 8.5mm, Power: -0.50D , Dia: 14.2mm ) Was prepared. For this test contact lens, the refractive index was measured by a general measurement method according to JIS K0062. That is, each of the liquid and the Japanese Pharmacopoeia purified water of Example 120 to 133 The test contact lens (hereinafter, purified water) was dipped respectively 4 hours, Abbe refractometer (Co. Atago Ltd. 1T) using , the refractive index was measured (sodium -D line) at 20 ° C. of the co Ntakutoren's.

Contact lenses for the test attached to each liquid agent using five were 5 times of measurement. Refractive index obtained for each solution, based on the refractive index of the immersion in purified water test contact lenses, the improvement rate for it was evaluated by determining by the following equation. In Table 14, the refractive index improvement rate was determined by the formula 1 from the refractive index measured 5 times for each liquid, and the average value was listed.
[Formula 1]
Refractive index improvement rate (%) = ({(refractive index when using each liquid agent) / (refractive index when using purified water)}-1) × 100

As shown in Table 14, the use of the ophthalmic composition liquid of Example 120 to 130 of the present invention, for testing Te contact lens odor, compared to the case of using purified water, 2.5% or more 10% The following refractive index improvement rate was secured, and it was found that the refractive index improvement function by the ophthalmic composition liquid according to the present invention was stably exhibited.

[Prescription Examples 1-36]
Formulation Examples 1-36 are shown in Tables 15-17. When each compound is mixed in the composition as shown in Tables 15 and 16 to make a composition solution, eye drops, wearing agents, contact lens packaging solutions, contact lens multipurpose solutions, contact lens disinfectants, contact lens cleaners, contacts The present invention can be applied to various uses such as a lens preservative and a contact lens rinse solution. In Table 17, more specific application examples are shown as formulation examples 25 to 36. With regard to Formulation Examples 25 and 26, after preparation of the preparation, aseptic filtration was performed and filled into a polyethylene terephthalate container (capacity 500 mL). Moreover, about the prescription examples 27-31 and the prescription examples 33-36, the preparation was aseptically filtered and filled in the container (capacity | capacitance 20 mL or less) obtained by the biaxial stretch blow molding. In addition, about the formulation example 32, it filled after the aseptic filtration of a formulation with the blow-fill-seal manufacturing method (container material: low density polyethylene: capacity | capacitance 0.4mL). In addition, about the prescription examples 25-36 except the prescription example 32, the method of ISO14730 (2000) was applied mutatis mutandis, and the expiration date after opening was set.

  The ophthalmic composition liquid of the present invention and its method of use include eye drops, wearing drugs, contact lens packaging liquids, contact lens multipurpose liquids, contact lens bactericides, contact lens cleaners, contact lens preservatives, contact lens rinses, etc. It can be used for various applications.

Claims (5)

0.001 mass of polyoxyethylene-polyoxypropylene glycol in which the ratio EO / PO of the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is in the range of 1.0 to 5.0 % and component a containing in the range of 5 wt% or less, and component B on one or more selected from polycarboxylic acids and polycarboxylic acid salts, 1.0% by mass or less as freshening agent L- Menthol component C, the IC50 value is 1.0% or more, and the concentration of dibutylhydroxytoluene (BHT) in the composition is less than 1.5 ppm (provided that olopatadine hydrochloride is 0.02 w) / V% to 0.1 w / v% are excluded), can be used for hard contact lenses manufactured by a mold manufacturing method ,
The component B is sodium hyaluronate, and is contained in the range of 0.001% by mass to 0.5% by mass,
An ophthalmic composition liquid having a base curve change suppression effect index calculated by the formula (1) of 97.9 or more .
Inhibitory effect index = 100 × [α (%) − BC change rate (%)] / α (%) (1)
(However, α is the base curve change rate (%) in the formulation in which the same copolymer is blended in the same blending amount and does not contain component B). The ophthalmic composition solution includes tetrahydrozoline hydrochloride, naphazoline, neostigmine methyl sulfate, berberine, sodium azulene sulfonate, chlorpheniramine maleate, ketotifen fumarate, sodium flavin adenine dinucleotide, cyanocobalamin, pyridoxine hydrochloride, tocopherol acetate, sulfa methoxazole, latanoprost, nipradilol, rebamipide, benzalkonium chloride, benzethonium chloride, sodium chloride, boric acid, zinc sulfate, zinc lactate, further comprising at least one component D selected from calcium chloride, according to claim 1 Ophthalmic composition liquid. The ophthalmic composition liquid according to claim 1 or 2 , wherein the lipid adhesion inhibitory effect calculated by the mathematical formula (2) is 54.9% or more.
Lipid adhesion inhibitory effect (%) = 100 × {1- (Sample quantitative result (mg / cm ² ) / Control quantitative result (mg / cm ² ))} Equation (2) The ophthalmic composition liquid includes eye drops, artificial tears, contact lens mounting liquid, contact lens mounting liquid, contact lens cleaning agent, contact lens preservative, contact lens cleaning preservative, contact lens rinsing liquid, contact lens package. The ophthalmology according to any one of claims 1 to 3 , wherein the ophthalmology is applied in the same prescription when at least one selected from a ling solution, a contact lens multipurpose solution, and a contact lens sterilizing solution. Composition liquid. 0.001 mass of polyoxyethylene-polyoxypropylene glycol in which the ratio EO / PO of the average degree of polymerization (EO) of ethylene oxide and the average degree of polymerization (PO) of propylene oxide is in the range of 1.0 to 5.0 % and component a containing in the range of 5 wt% or less, and component B on one or more selected from polycarboxylic acids and polycarboxylic acid salts, 1.0% by mass or less as freshening agent L- Menthol component C, the IC50 value is 1.0% or more, and the concentration of dibutylhydroxytoluene (BHT) in the composition is less than 1.5 ppm (provided that olopatadine hydrochloride is 0.02 w). Ophthalmic composition liquid can be used for hard contact lenses manufactured by a mold manufacturing method, except for those containing / v% to 0.1 w / v% ,
The component B is sodium hyaluronate, and is contained in the range of 0.001% by mass to 0.5% by mass,
The base curve change suppression effect index calculated by Equation (1) is 97.9 or more,
How to use ophthalmic composition liquid.
Inhibitory effect index = 100 × [α (%) − BC change rate (%)] / α (%) (1)
(However, α is the base curve change rate (%) in the formulation in which the same copolymer is blended in the same blending amount and does not contain component B).